In a small retrospective pilot study, the checkpoint inhibitor tislelizumab added to gemcitabine/cisplatin improved progression-free survival compared with gemcitabine/cisplatin alone among patients with locally advanced or metastatic bladder cancer.
Authors say Gem/Doce warrants further study for the treatment of BCG-naive high-risk non-muscle-invasive bladder cancer
The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested.
An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.
Adding docetaxel to standard care improved failure-free survival and progression-free survival (PFS) but not overall survival, metastatic PFS, or prostate cancer-specific survival.
Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.
Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
However, a history of cancer more than one year before COVID-19 diagnosis not tied to increased mortality or hospitalization
